Previous Article | Next Article ![]()
Journal of Virology, July 2007, p. 7380-7387, Vol. 81, No. 14
0022-538X/07/$08.00+0 doi:10.1128/JVI.00222-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

and
Tony Minson
Division of Virology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United Kingdom
Received 1 February 2007/ Accepted 3 May 2007
|
|
|---|
|
|
|---|
Herpesviruses are ubiquitous pathogens of vertebrates, and infections by members of this family are associated with a wide variety of human and animal diseases (29). Herpesviruses are some of the most complex viruses known: they are composed of a double-stranded DNA genome encased in an icosahedral capsid, a layer of more than 15 different proteins known as the tegument, and a host-derived envelope containing 10 or more different viral glycoproteins (23). The assembly of herpesviruses begins in the nucleus of an infected cell, where newly synthesized genomes are packaged into preformed capsids. These nucleocapsids then undergo budding at the inner nuclear membrane to form an enveloped particle in the perinuclear space, followed by a fusion event at the outer nuclear membrane, releasing the nucleocapsids into the cytoplasm. Mature virus particles are then formed by the budding of the nucleocapsids and tegument into vesicles derived from the trans-Golgi network (TGN) or endosomes (33). Mature virions are released from cells by fusion of the vesicles containing mature virus with the plasma membrane, in a mechanism akin to exocytosis (reviewed in references 23 and 24). Evidence from a number of herpesviruses suggests that this assembly pathway is conserved among the three viral subfamilies Alpha-, Beta-, and Gammaherpesvirinae (13). Therefore, the mechanisms involved in herpesvirus assembly have been conserved for at least 400 million years of virus coevolution with host (21).
This complex assembly regimen for the production and release of new herpesviruses requires the budding of viral nucleocapsids and tegument proteins into the lumen of cytoplasmic organelles, and this remains a poorly understood process with no known requirement for cellular proteins. Several viral tegument proteins are thought to play critical roles in cytoplasmic envelopment, based mainly on evidence from the phenotypes of deletion mutants of herpes simplex virus type 1 (HSV-1) and pseudorabies virus (both alphaherpesviruses) and cytomegalovirus (a betaherpesvirus). These include homologues of the HSV-1 UL11 and UL36 genes (7, 11, 18, 30), the alphaherpesvirus UL48 and UL51 genes (10, 17, 26, 27), and the cytomegalovirus UL32 gene (1). In contrast, the role of viral envelope proteins in cytoplasmic envelopment appears to be subtle, with little effect of gene deletions unless multiple envelope proteins are absent (5, 8). Whether any of these viral proteins can function in a manner equivalent to that of the L-domain-containing proteins found in enveloped RNA viruses, to recruit ESCRT proteins, is unknown.
The cellular MVE budding machinery consists of the multiprotein complexes ESCRT-1, -2, and -3 together with several additional proteins (15), and this machinery is normally responsible for the sorting of proteins into MVE luminal vesicles that are destined for degradation in lysosomes (14, 31). As the budding of herpesvirus nucleocapsids into the lumen of TGN or endosome-derived vesicles shares similarities with the formation of luminal vesicles in MVEs, it seems possible that these viruses could have evolved mechanisms to use the ESCRT machinery in the formation of infectious viruses. Consistent with this hypothesis is the observation that assembled human cytomegalovirus virions have been observed in organelles showing MVE morphology (9). We now show that inhibition of activity of Vps4, an enzyme that is crucial for ESCRT function and MVE luminal vesicle formation (2), causes a severe defect in the production of infectious HSV-1. Analysis of the different stages of the viral life cycle demonstrates that functional Vps4 is required for the cytoplasmic envelopment of HSV-1.
|
|
|---|
UL36) and a UL36-complementing cell line (HS30) were from P. Desai (Johns Hopkins University) (7). Antibodies to green fluorescent protein (GFP) were obtained from Abcam (Ab6556) and Clontech (JL8). Antibodies that recognize HSV-1 VP1/2 were generously provided by Peter O'Hare (Marie Curie Research Institute, Oxted, United Kingdom). Antiactin was obtained from Sigma (AC-40), and anti-VP16 (LP1) has been previously described (22). Plasmids. pEGFPC-Vps4WT and pEGFPC-Vps4EQ were from P Woodman (Manchester University) (4). pCR3.1-YFPVps4WT, pCR3.1-YFPVps4EQ, and pCR3.1-GFP were from J. Martin-Serrano (Kings College London). The enhanced GFP (EGFP) open reading frame was excised from pEGFPC2 (Clontech) with NheI and XbaI and ligated into pIND(SP1) (Invitrogen), which had been cut with the same enzymes, to make pIND-GFP. The Vps4WT and Vps4EQ coding sequences were excised from pEGFP-Vps4WT and pEGFP-Vps4EQ, respectively, with BsrGI and BamHI and ligated into pIND-GFP, which had been cut with the same enzymes, to make pIND-GFPVpsWT and pIND-GFPVps4EQ, respectively. The 5' end of HSV-1 UL36 was excised from pSG124 (pBR325 containing EcoRI fragment A of the HSV-1 strain KOS genome) (12) with HindIII and EcoRI and ligated into pcDNA3 to generate pcDNA3-UL36-5'end. The 3' end of UL36 was excised from pSG3 (pBR325 containing EcoRI fragment L of the HSV-1 strain KOS genome) (12) with EcoRI, ligated into pcDNA3-UL36-5'end cut with EcoRI, and screened for correct orientation. The resulting pcDNA3-UL36 plasmid contained the entire HSV-1 UL36 open reading frame with 170 bp of 5' genomic sequence and 1,352 bp of 3' genomic sequence.
Complementation assay.
Cos7 cells were seeded into six-well dishes at 2 x 105 cells per well and transfected with 2 µg pCR3.1-GFP alone or 1 µg pcDNA3-UL36 together with 1 µg of pCR3.1-GFP, pCR3.1-YFPVps4WT, or pCR3.1-YFPVps4EQ. After 24 h, cells were infected with HSV-1
UL36 at 10 PFU/cell, and unabsorbed virus was inactivated by treatment with acid wash (40 mM citric acid, 135 mM NaCl, 10 mM KCl, pH 3.0). At 16 h postinfection (hpi) samples were harvested by scraping. Three samples of each condition were sonicated for 20 seconds at 40% amplitude followed by freeze-thawing to liberate cell-associated virus. Infectious viral titers were determined by plaque assays on HS30 cells (7). The cells from a fourth sample of each condition were harvested by centrifugation and resuspended in lysis buffer (50 mM Tris, pH 7.9, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate) supplemented with protease inhibitor cocktail (Roche) and incubated on ice for 20 min. Lysates were clarified by centrifugation at 13,000 rpm for 20 min at 4°C. Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), proteins were transferred to nitrocellulose and the expression levels of VP1/2- and GFP-tagged proteins were determined using anti-VP1/2 or anti-GFP (JL8) and chemiluminescence detection.
Ecdysone-responsive stable cell lines. EcR-293 cells were transfected with pIND-GFPVps4WT or pIND-GFPVps4EQ and placed under selection in complete Dulbecco's modified Eagle's medium supplemented with 400 µg/ml Zeocin and 800 µg/ml G418. Single clones were isolated by limiting dilution, and samples of each clone were screened by fluorescence microscopy and Western blotting after addition of 1 µM ponA. Clones demonstrating GFP fluorescence in all cells were maintained. One clone of each cell line showing comparable levels of inducible expression in the presence of ponA by Western blotting was chosen for further experiments. 293-Vps4WT and 293-Vps4EQ cells were treated with or without 1 µM ponA for various times, and cellular proteins were extracted as described above. Following SDS-PAGE, proteins were transferred to nitrocellulose and the expression of Vps4 proteins was determined with anti-GFP (Ab6556) and chemiluminescence detection. Cells grown on glass coverslips were fixed 16 h after ponA addition and analyzed with an Olympus IX70 fluorescence microscope. Images were captured using a Reitga 2000R charge-coupled device camera and ImageQ software and processed using Adobe Photoshop.
HSV-1 growth assays. 293-Vps4WT and 293-Vps4EQ cells were treated with or without 1 µM ponA for 16 h and infected with HSV-1 (SC16) at 10 PFU/cell, and unabsorbed virus was inactivated with acid wash. At various times, samples were harvested as described above. Infectious viral titers were determined by plaque assays on Vero cells. The expression levels of GFP-Vps4 proteins, VP16, and actin in protein extracts from samples at various times postinfection were analyzed by Western blotting with anti-GFP (JL8), anti-VP16 (LP1), or antiactin (AC-40) as described above.
Quantitative real-time PCR. 293-Vps4WT and 293-Vps4EQ cells were treated with or without 1 µM ponA for 16 h and infected with HSV-1 (SC16) at 10 PFU/cell, and unabsorbed virus was removed by acid wash. Cells were harvested at 16 hpi and treated with 10 mM Tris, pH 8.0, 50 mM EDTA, 0.5% SDS, 0.2 mg/ml proteinase K for 18 h at 37°C. Samples were sonicated three times for 30 seconds each at 40% amplitude, and DNA was extracted with a QIAquick PCR purification kit (QIAGEN). Real-time PCR was performed using a Rotorgene (Corbett Research) in triplicate for each sample. Primers and high-pressure liquid chromatography-purified probes were designed by Tib-MolBiol (Berlin). A primer set for the detection of HSV-1 genomes was based on the ICP0 gene promoter region with the following HSV-1 sequence coordinates: forward primer, 2072 to 2090; reverse primer, 2209 to 2139; and TaqMan probe, 2115 to 2134, where the ICP0 transcription start site is 2115. A primer set for the detection of cellular genomes was based on the human glyceraldehyde-3-phosphate dehydrogenase gene promoter region with the following gene coordinates: forward primer, 1725 to 1744; reverse primer, 1913 to 1894; and TaqMan probe, 1913 to 1894, where numbers are relative to a transcription start site of 1874 based on comparison of genomic and cDNA sequences (accession no. AY340484). Results from the real-time PCRs were quantified as copy number per sample using the Rotorgene software from standard curves that were generated using known amounts of plasmids containing each of the relevant DNA regions. The mean of each triplicate data set for ICP0 was divided by the mean of the triplicate glyceraldehyde-3-phosphate dehydrogenase data set from the same DNA sample to obtain estimates of HSV-1 genome copies present per cell.
[35S]methionine labeling. 293-Vps4WT and 293-Vps4EQ cells were treated with 1 µM ponA for 16 h and infected with HSV-1 (SC16) at 10 PFU/cell, and unabsorbed virus was inactivated by acid wash. At 7 hpi, cells were washed and incubated in methionine-free medium for 1 h followed by [35S]methionine labeling for 16 h. Cells were harvested and lysed as described above, and protein extracts were analyzed by SDS-PAGE and autoradiography.
Electron microscopy (EM). Infected-cell samples were harvested and fixed in either 2.5% glutaraldehyde and 2% paraformaldehyde in 100 mM sodium cacodylate or 4% glutaraldehyde in 100 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid); pH 7.4] containing 2 mM CaCl2 for 2 h at room temperature. Cells were washed in 50 mM Tris (pH 7.4) containing 2 mM CaCl2, treated with 1% osmium tetroxide for 30 min, and rinsed in distilled water. Samples were then stained with 2% uranyl acetate for 30 min, rinsed with distilled water, dehydrated in methanol, infiltrated with Spurr's epoxy resin over 5 days, and cured at 60°C. Fifty-nanometer sections were cut using a Leica Ultracut S microtome and mounted on uncoated copper grids. Samples were counterstained with uranyl acetate and lead citrate and viewed with a Philips CM100 transmission electron microscope, and images were recorded on Kodak 4489 cut film. Negatives were scanned at 1,200 dots per inch and processed using Adobe Photoshop.
|
|
|---|
Transient expression of nonfunctional Vps4 reduces the yield of infectious HSV-1.
As an initial approach to determine whether Vps4 plays a role in the assembly of HSV-1 virions, cells transfected with plasmids expressing wild-type or dominant-negative Vps4 were infected with HSV-1 and the progeny virus was assayed. To avoid problems associated with variable transfection efficiencies and replication of HSV-1 in untransfected cells, a complementation assay was used. HSV-1 lacking the essential gene UL36 (HSV-1
UL36) does not produce infectious virus unless the defect is complemented through provision of UL36 expression in trans (7). If the provision of UL36 expression is through transient transfection, then transfected cells will be the only source of infectious progeny. Therefore, cotransfection of UL36 and Vps4 expression plasmids, followed by infection with HSV-1
UL36, will mean that the vast majority of progeny virus will have to be produced in the presence of plasmid-expressed Vps4, and so the effect of dominant-negative Vps4 can be assessed more reliably.
Cells were transfected with plasmids expressing UL36 together with wild-type or dominant-negative Vps4 (Vps4WT or Vps4EQ, respectively) or control plasmids and subsequently infected with HSV-1
UL36. The virus yields were assayed on a UL36-complementing cell line to allow plaque formation (7). The UL36 complementation assay system demonstrated approximately an 80-fold difference in the production of infectious HSV-1 progeny between cells expressing GFP together with UL36 in trans and cells expressing GFP alone (with no UL36) (Fig. 1A). Expression of yellow fluorescent protein (YFP)-Vps4EQ with UL36 resulted in a reduction in progeny HSV-1 titer by
50-fold compared to expression of GFP with UL36. Expression of UL36 with YFP-Vps4WT showed a small reduction in HSV-1 titer (
2-fold). GFP, YFP-Vps4WT, and YFP-Vps4EQ were all expressed to similar levels in these assays, and the expression of UL36 from transfected plasmids was unaffected by the coexpression of Vps4WT or Vps4EQ (Fig. 1B). These results are similar to those reported using HIV: namely, overexpression of wild-type Vps4 gave a minor dominant-negative effect, resulting in a slightly smaller yield of HIV, whereas a major dominant-negative effect resulting in a large reduction in HIV yield was observed in the presence of Vps4EQ (34). Similar complementation experiments were performed using a glycoprotein-H-null HSV-1 and transfection of cells with glycoprotein-H-expressing plasmids as previously described (35). These experiments generated very similar results, with coexpression of YFP-Vps4EQ leading to a significant decrease in infectious HSV-1 (
10-fold). These data suggest that the inhibition of HSV-1 growth in the presence of Vps4EQ is independent of which complementation system is used. Therefore, functional Vps4 appears to be required for the production of infectious HSV-1 particles.
![]() View larger version (24K): [in a new window] |
FIG. 1. The effect of transient Vps4EQ expression on the production of infectious HSV-1. Cells transfected with a UL36 expression plasmid in the presence of GFP, YFP-Vps4WT, or YFP-Vps4EQ expression plasmids or cells transfected with a GFP expression plasmid alone were infected with HSV-1 UL36. (A) Progeny viral titers were determined by plaque assay on a UL36-complementing cell line. Bars represent mean PFU/ml, and error bars represent 1 standard deviation from the mean of triplicate samples. (B) Protein extracts were analyzed by Western blotting with VP1/2- and GFP-specific antibodies.
|
![]() View larger version (46K): [in a new window] |
FIG. 2. Single-step growth curves of HSV-1 in Vps4WT- and Vps4EQ-expressing cell lines. Clonal 293 cell lines expressing GFP-Vps4WT or GFP-Vps4EQ under the control of the ecdysone response element were isolated. (A) Cells were treated with 1 µM ponA for various times, and protein extracts were analyzed by Western blotting with a GFP-specific antibody. Fluorescence microscope images were collected at 16 h after ponA addition. Numbers at left are molecular masses in kilodaltons. (B) Cells were treated with or without ponA for 16 h and infected with HSV-1, and progeny virus was harvested at various times. Infectious viral titers were determined by plaque assay. Data represent mean PFU/ml, and error bars represent 1 standard deviation from the mean of triplicate samples. (C) Protein extracts were harvested from infected cells at various times postinfection and analyzed by Western blotting with GFP-, VP16-, and actin-specific antibodies.
|
100-fold reduction in the production of infectious HSV-1.
The effect of dominant-negative Vps4 on viral genome and protein synthesis.
Although Vps4EQ inhibits ESCRT-mediated membrane budding, the inhibition of HSV-1 replication could potentially be due to secondary effects on other aspects of the virus life cycle, rather than a specific effect on cytoplasmic envelopment of nucleocapsids. As a first step to identify the stage of HSV-1 infection that is inhibited in these cells, the viral genome load was analyzed. Cells were treated with or without ponA and then infected with HSV-1. DNA was isolated from each sample at 16 hpi, and the HSV-1 and cellular genome copy numbers were determined by real-time PCR. Induction of Vps4EQ appeared to have a minor effect on viral genome synthesis (
3-fold reduction; Fig. 3A), but this is unlikely to account for the large reduction in infectious virus yield.
![]() View larger version (26K): [in a new window] |
FIG. 3. HSV-1 genome and protein synthesis. 293-Vps4WT and 293-Vps4EQ cells were treated with 1 µM ponA or not and infected with HSV-1. (A) DNA samples were harvested at 16 hpi, and the copy numbers of HSV-1 and cellular genomes were determined by real-time PCR. Data are shown as mean numbers of HSV-1 genome copies per cell. (B) Infected cells were labeled with [35S]methionine, and protein samples were harvested at 24 hpi. Radiolabeled proteins were detected by autoradiography following SDS-PAGE. The positions of various viral proteins, as expected from previous publications, are shown. Numbers at left are molecular masses in kilodaltons.
|
Taken together, these data demonstrate that expression of Vps4EQ has little or no effect on viral genome synthesis, the overall accumulation of viral proteins, or the rate of expression of a major viral protein, VP16. Therefore, Vps4EQ expression does not appear to inhibit viral entry or the production of the viral structural components.
Dominant-negative Vps4 inhibits the production of enveloped virus particles. To determine the effect of Vps4EQ expression on HSV-1 assembly at the ultrastructural level, cells expressing Vps4WT or Vps4EQ were infected with HSV-1 and analyzed by EM. In Vps4WT-expressing cells, all stages of HSV-1 assembly could be visualized: nucleocapsids in the nucleus and extracellular virions (Fig. 4A), perinuclear enveloped particles (Fig. 4B), and fully enveloped virions contained within vesicles and some unenveloped capsids in the cytoplasm (Fig. 4C). In Vps4EQ-expressing cells nucleocapsids in the nucleus and perinuclear enveloped particles could be identified at a frequency similar to that in Vps4WT cells (Fig. 4D and E). However, no extracellular virus particles were observed, and only unenveloped capsids were present within the cytoplasm with an almost complete absence of any fully enveloped virions (Fig. 4F to J). Interestingly, cytoplasmic capsids within Vps4EQ cells were usually associated with membranes, with some virions almost completely enveloped but not fully surrounded by membrane (Fig. 4H to J; arrowheads indicate the membrane edges). These data demonstrate two points: firstly, inhibition of Vps4 function appears to have no effect on capsid assembly or nucleocapsid egress from the nucleus, and secondly, expression of Vps4EQ inhibits HSV-1 final envelopment in the cytoplasm, and this inhibition of cytoplasmic envelopment can occur at late stages of assembly.
![]() View larger version (200K): [in a new window] |
FIG. 4. EM analysis of infected cells. 293-Vps4WT and 293-Vps4EQ cells were induced with ponA and infected with HSV-1. At 15 hpi, cells were fixed, processed, and analyzed by transmission EM. Bars, 500 nm (A) or 200 nm (B to J).
|
80%) of unenveloped cytoplasmic capsids observed in both cell lines were physically close to membranes, suggesting that they were partially assembled. Interestingly, of these membrane-associated capsids, very few appeared almost fully enveloped (as in Fig. 4H to J) in Vps4WT cells, whereas many membrane-associated capsids (
12%) in the cytoplasm of Vps4EQ cells demonstrated this type of morphology. Taken together, these EM data suggest that the assembly of infectious HSV-1 requires Vps4 activity for the successful budding of virions at cytoplasmic membranes. |
View this table: [in a new window] |
TABLE 1. Quantification of HSV-1 particles in Vps4WT and Vps4EQ cells
|
|
|
|---|
In experiments demonstrating a reduction in infectious virus yields it is always important to determine whether the observed reduction is due to the failure to assemble virus particles or due to the assembly of particles that have reduced infectivity. Our data show that the inhibition of Vps4 function does indeed inhibit viral assembly: EM quantification demonstrates an almost total lack of enveloped virus when Vps4 activity is inhibited. A further question that is difficult to answer unequivocally is whether defects in viral assembly that are caused by inhibiting membrane traffic pathways (such as ESCRT protein inhibition) are due to a direct inhibition of the membrane budding mechanism or arise from secondary effects of mislocalizing a subset of viral components to the incorrect compartment(s) so that they are not available to participate in assembly. Our EM observations indicate that envelopment of HSV-1 can initiate in Vps4EQ cells and can proceed almost to completion. These "partially enveloped" virions are otherwise morphologically similar to those observed in normal cells. It appears, therefore, that in Vps4EQ cells all the viral proteins that are necessary for the interaction of capsids and tegument with membranes to drive envelopment to late stages must be present on these structures, but envelopment cannot be completed. The obvious interpretation is that functional Vps4 is directly involved in completion of the envelopment (i.e., budding) process of HSV-1. It is also possible that inhibition of certain membrane traffic pathways could result in a block of secretion, thereby interfering with the release of HSV-1 from cells. However, it seems unlikely that expression of dominant-negative Vps4 is reducing HSV-1 titer simply by inhibiting the release of enveloped virions via secretion; otherwise, similar or even greater numbers of enveloped virions contained within cytoplasmic vesicles would be expected, whereas we observe a dramatically reduced number of enveloped virions in the cytoplasm (>20-fold). Furthermore, previous reports have demonstrated that the expression of dominant-negative Vps4 does not affect the localization of secretory pathway proteins, including markers of the endoplasmic reticulum, Golgi compartment, and TGN (4, 36).
Enveloped RNA viruses recruit the ESCRT machinery to sites of viral budding through the interaction of viral L-domain motifs with ESCRT proteins. At least three classes of L-domain motifs have been identified: P-T/S-A-P motifs, Y-P-x-L motifs, and P-P-x-Y motifs (3, 6, 25). The majority of these RNA viruses express proteins that contain one or two L-domain motifs that are necessary and sufficient for the recruitment of ESCRT proteins. The situation with herpesviruses is likely to be more complex. All three classes of L-domain motifs are present in several HSV-1 structural proteins including major capsid protein (VP5), the tegument protein VP16, the very large tegument protein VP1/2, the cytoplasmic domain of glycoprotein E, and at least three additional tegument proteins. This frequency of L-domain motif occurrence in HSV-1 virion components may signify the importance of engaging ESCRT proteins for the assembly of infectious virions and may also reflect the functional redundancy of different proteins in herpesvirus assembly (24). Such redundancy of function may allow for the loss of any one or more L-domain motifs without inhibiting virus production but complicates the analysis of the role of such motifs by mutagenesis. Interestingly, of all the HSV-1 tegument and envelope proteins containing potential L-domain motifs, VP1/2 is the only one conserved throughout all alpha-, beta-, and gammaherpesviruses, and mutants lacking VP1/2 are defective in cytoplasmic envelopment (7, 11). The VP1/2 protein of HSV-1 contains all three classes of L-domain motifs that could potentially interact with ESCRT proteins, and at least one L-domain motif appears to be present in all VP1/2 homologues analyzed, an observation of some significance given that the respective genes diverged in evolution approximately 400 million years ago (21). It is therefore tempting to speculate that VP1/2 may function in part by recruiting ESCRT components to sites of herpesvirus envelopment.
In summary, it appears that the ESCRT pathway provides the budding machinery for a wide variety of enveloped viruses, which we suggest include HSV-1, where the interactions of a large number of virus-specific proteins are involved in assembly and envelopment. In some cases, budding of viruses has been observed at MVEs, the normal sites of action of the ESCRT machinery (9, 19), but in other cases it is clear that viruses can recruit ESCRT components to alternative compartments, such as the plasma membrane (20). In the case of herpes simplex virus it is apparent that the budding compartment lacks the morphological characteristics of MVEs, but the precise nature of the compartment remains unknown.
UL36 and HS30 cells, J. Powell (Multi-Imaging Centre, Cambridge University) for help with EM sample preparation, and H. Browne for helpful discussion and critical reading of the manuscript. This work was funded by the Royal Society (University Research Fellowship to C.M.C.) and the Wellcome Trust (program grant no. 68075).
Published ahead of print on 16 May 2007. ![]()
Catherine Yates sadly died during the preparation of the manuscript. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»